CANbridge Pharma Overview
- Founded
-
2012

- Status
-
Public
- Employees
-
183

- Stock Symbol
-
01228

- Share Price
-
$0.50
- (As of Monday Closing)
CANbridge Pharma General Information
Description
Canbridge Pharmaceuticals Inc is a global biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.
Contact Information
- Suite 301,3F,Timeloit, No. 17 RongChuang Road
- Chaoyang District
- Beijing
- China
CANbridge Pharma Timeline
CANbridge Pharma Stock Performance
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.50 | $0.49 | $0.46 - $1.28 | $211M | 424M | 19.1K | -$1.77 |
CANbridge Pharma Financials Summary
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 821,444 | 821,444 | ||
Revenue | 4,826 | 4,826 | 1,742 | 213 |
EBITDA | (164,289) | (164,289) | (119,470) | (30,811) |
Net Income | (166,795) | (166,795) | (122,462) | (31,503) |
Total Assets | 140,023 | 140,023 | 89,749 | 12,656 |
Total Debt | 8,174 | 8,174 | 7,178 | 10,044 |
CANbridge Pharma Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
CANbridge Pharma Comparisons
Industry
CANbridge Pharma Competitors (56)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Genkyotex | Corporate Backed or Acquired | Saint-Julien- en-Genevois, France | 00 | 000.00 | 000000&0 | 000.00 |
000000000 00000000 | Formerly VC-backed | San Francisco, CA | 000 | 00000 | 000000&0 | 00000 |
000000000 00000000 | Formerly VC-backed | Guangzhou, China | 000.00 | 00000000000 | ||
0000000 0000000000 | Formerly VC-backed | Shanghai, China | 000 | 00000 | 00000000 | 00000 |
000 000000000000 | Formerly VC-backed | Epalinges, Switzerland | 000 | 00.000 | 00000000 | 00.000 |
CANbridge Pharma Patents
CANbridge Pharma Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-3644062-A4 | Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit | Pending | 22-Jun-2017 | 0000000000 | 0 |
EP-3644062-A1 | Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit | Pending | 22-Jun-2017 | 000000000 | |
US-20210025006-A1 | Method for predicting response of esophagus cancer to anti-erbb3 antibody therapy, and kit | Pending | 22-Jun-2017 | 000000000000 | |
JP-2020524808-A | Methods and kits for predicting esophageal cancer response to anti-erbb3 antibody treatment | Pending | 22-Jun-2017 | G01N33/57407 |
CANbridge Pharma Executive Team (13)
CANbridge Pharma Board Members (4)
Name | Representing | Role | Since |
---|---|---|---|
Guangping Gao Ph.D | Self | Board Member | 000 0000 |
Mark Bamforth | CANbridge Pharma | Board Member | 000 0000 |
Qun Xue Ph.D | CANbridge Pharma | Founder, Chief Executive Officer and Chairman | 000 0000 |
CANbridge Pharma Signals
CANbridge Pharma Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|